2024-03-28T18:20:26Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/2147052021-12-27T16:31:18Zcom_10261_79com_10261_1col_10261_332
G protein-coupled receptor kinase 2 (GRK2) as a potential therapeutic target in cardiovascular and metabolic diseases
Murga, Cristina
Arcones, Alba C.
Cruces-Sande, Marta
Briones, Ana M.
Salaices, Mercedes
Mayor Méndez, Federico Jr.
Ministerio de Economía, Industria y Competitividad (España)
Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (España)
Instituto de Salud Carlos III
Comunidad de Madrid
GRK2
GPCR
Cardiovascular
Obesity
NAFLD
Insulin resistance
Inhibitors
G protein-coupled receptor kinase 2 (GRK2) is a central signaling node involved in the modulation of many G protein-coupled receptors (GPCRs) and also displaying regulatory functions in other cell signaling routes. GRK2 levels and activity have been reported to be enhanced in patients or in preclinical models of several relevant pathological situations, such as heart failure, cardiac hypertrophy, hypertension, obesity and insulin resistance conditions, or non-alcoholic fatty liver disease (NAFLD), and to contribute to disease progression by a variety of mechanisms related to its multifunctional roles. Therefore, targeting GRK2 by different strategies emerges as a potentially relevant approach to treat cardiovascular disease, obesity, type 2 diabetes, or NAFLD, pathological conditions which are frequently interconnected and present as co-morbidities.
2020-06-18T08:10:04Z
2020-06-18T08:10:04Z
2019-02-19
2020-06-18T08:10:04Z
artículo
Frontiers in Pharmacology 10 (2019)
http://hdl.handle.net/10261/214705
10.3389/fphar.2019.00112
http://dx.doi.org/10.13039/501100010198
http://dx.doi.org/10.13039/501100004587
http://dx.doi.org/10.13039/100012818
30837878
Publisher's version
http://dx.doi.org/10.3389/fphar.2019.00112
Sí
https://creativecommons.org/licenses/by/4.0/
openAccess